{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:04:41Z","timestamp":1766023481755,"version":"3.48.0"},"reference-count":30,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/kmcl5401","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T03:15:45Z","timestamp":1730344545000},"page":"5880-5889","source":"Crossref","is-referenced-by-count":0,"title":["Clinical effectiveness and safety of Camrelizumab immunotherapy in treating advanced esophageal carcinoma"],"prefix":"10.62347","volume":"16","author":[{"given":"Yusheng","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"816270","DOI":"10.3389\/fonc.2022.816270","article-title":"Perineural invasion is a significant indicator of high malignant degree and poor prognosis in esophageal cancer: a systematic review and meta-analysis","volume":"12","author":"Bai","year":"2022","unstructured":"Bai L, Yan L, Guo Y, He L, Sun Z, Cao W, Lu J and Mo S. Perineural invasion is a significant indicator of high malignant degree and poor prognosis in esophageal cancer: a systematic review and meta-analysis. Front Oncol 2022; 12: 816270.","journal-title":"Front Oncol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/ijc.34301","article-title":"Esophageal cancer in China: practice and research in the new era","volume":"152","author":"Zhu","year":"2023","unstructured":"Zhu H, Ma X, Ye T, Wang H, Wang Z, Liu Q and Zhao K. Esophageal cancer in China: practice and research in the new era. Int J Cancer 2023; 152: 1741-1751.","journal-title":"Int J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"12804","DOI":"10.12998\/wjcc.v10.i35.12804","article-title":"Principle and progress of radical treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Zhang","year":"2022","unstructured":"Zhang XF, Liu PY, Zhang SJ, Zhao KL and Zhao WX. Principle and progress of radical treatment for locally advanced esophageal squamous cell carcinoma. World J Clin Cases 2022; 10: 12804-12811.","journal-title":"World J Clin Cases"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, Wang F, Feng S, Peng F, Wang X, Chen S, He M, Zhang N, Wang H, Zeng B, Liu Z, Kidane B, Seder CW, Koyanagi K, Shargall Y, Luo H, Peng S and Cheng C. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer 2022; 10: e003497.","DOI":"10.1136\/jitc-2021-003497"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","unstructured":"Tang H, Wang H, Fang Y, Zhu JY, Yin J, Shen YX, Zeng ZC, Jiang DX, Hou YY, Du M, Lian CH, Zhao Q, Jiang HJ, Gong L, Li ZG, Liu J, Xie DY, Li WF, Chen C, Zheng B, Chen KN, Dai L, Liao YD, Li K, Li HC, Zhao NQ and Tan LJ. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol 2023; 34: 163-172.","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH and Wang F. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell 2022; 40: 277-288, e273.","DOI":"10.1016\/j.ccell.2022.02.007"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jamasurg.2021.0133","article-title":"neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial","volume":"156","author":"Wang","year":"2021","unstructured":"Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, Zeng Z, Zhu J, Hou Y, Du M, Jiao J, Jiang H, Gong L, Li Z, Liu J, Xie D, Li W, Lian C, Zhao Q, Chen C, Zheng B, Liao Y, Li K, Li H, Wu H, Dai L and Chen KN. Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs. neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial. JAMA Surg 2021; 156: 444-451.","journal-title":"JAMA Surg"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zhao W, Zhao J, Kang L, Li C, Xu Z, Li J and Zhang M. Fluoroscopy-guided salvage photodynamic therapy combined with nanoparticle albumin-bound paclitaxel for locally advanced esophageal cancer after chemoradiotherapy: a case report and literature review. Cancer Biother Radiopharm 2022; 37: 410-416.","DOI":"10.1089\/cbr.2020.4595"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"15187","DOI":"10.1002\/cam4.6205","article-title":"Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma","volume":"12","author":"Jiang","year":"2023","unstructured":"Jiang H, Li Q, Chen B, Xi M, Makelike K, Liu S, Hu Y and Zhu Y. Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Med 2023; 12: 15187-15198.","journal-title":"Cancer Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J and Xu RH; ESCORT-1st Investigators. Effect of camrelizumab vs. placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 2021; 326: 916-925.","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.3390\/cancers14205168","article-title":"Recent advances in combination of immunotherapy and chemoradiotherapy for locally advanced esophageal squamous cell carcinoma","volume":"14","author":"Wang","year":"2022","unstructured":"Wang R, Liu S, Chen B and Xi M. Recent advances in combination of immunotherapy and chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancers (Basel) 2022; 14: 5168.","journal-title":"Cancers (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1007\/s00262-023-03566-5","article-title":"Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer","volume":"72","author":"Li","year":"2023","unstructured":"Li N and Sohal D. Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer. Cancer Immunol Immunother 2023; 72: 3939-3952.","journal-title":"Cancer Immunol Immunother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12967-023-04273-6","article-title":"Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial","volume":"21","author":"Yang","year":"2023","unstructured":"Yang G, Su X, Huang Y, Luo G, Wang Z, Cai P, Zheng Y, Bei T, Huang M, Bai Y, He H, Xiang J, Cai M, Zhong J, Guo Q and Zhang X. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial. J Transl Med 2023; 21: 411.","journal-title":"J Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12885-022-09573-6","article-title":"Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)","volume":"22","author":"Yang","year":"2022","unstructured":"Yang Y, Zhu L, Cheng Y, Liu Z, Cai X, Shao J, Zhang M, Liu J, Sun Y, Li Y, Yi J, Yu B, Jiang H, Chen H, Yang H, Tan L and Li Z. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study). BMC Cancer 2022; 22: 506.","journal-title":"BMC Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-20-4691","article-title":"Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Peng","year":"2021","unstructured":"Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K, Cheng Y, Yuan X, Xiao J, Tai Y, Wang L, Zou J, Zhang Y and Shen L. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 2021; 27: 3069-3078.","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"818626","DOI":"10.3389\/fonc.2022.818626","article-title":"Camrelizumab combined with gemcitabine and albumin-bound paclitaxel for neoadjuvant therapy in the treatment of progressive gallbladder cancer: a case report","volume":"12","author":"Wu","year":"2022","unstructured":"Wu J, Wang Z, Li J, Peng XH, Tang YC, Huang XB and He YG. Camrelizumab combined with gemcitabine and albumin-bound paclitaxel for neoadjuvant therapy in the treatment of progressive gallbladder cancer: a case report. Front Oncol 2022; 12: 818626.","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.1038\/s41598-022-09193-x","article-title":"Sex differences in esophageal cancer overall and by histological subtype","volume":"12","author":"Stabellini","year":"2022","unstructured":"Stabellini N, Chandar AK, Chak A, Barda AJ, Dmukauskas M, Waite K and Barnholtz-Sloan JS. Sex differences in esophageal cancer overall and by histological subtype. Sci Rep 2022; 12: 5248.","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J and Perez de la Lastra JM. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 2022; 10: 1367-1401.","journal-title":"Genes Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.3390\/jcm13144271","article-title":"Short- and long-term outcomes in elderly patients with resectable esophageal cancer: upfront esophagectomy compared to surgery after neoadjuvant treatments","volume":"13","author":"Moletta","year":"2024","unstructured":"Moletta L, Pierobon ES, Capovilla G, Zuin IS, Carrillo Lizarazo JL, Nezi G, Lonardi S, Murgioni S, Galuppo S, Zanchettin G, Salvador R, Provenzano L and Valmasoni M. Short- and long-term outcomes in elderly patients with resectable esophageal cancer: upfront esophagectomy compared to surgery after neoadjuvant treatments. J Clin Med 2024; 13: 4271.","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12957-021-02446-5","article-title":"Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study","volume":"19","author":"Yang","year":"2021","unstructured":"Yang P, Zhou X, Yang X, Wang Y, Sun T, Feng S and Ma X. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study. World J Surg Oncol 2021; 19: 333.","journal-title":"World J Surg Oncol"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G, Zhao J, Er P, Zhang T, Chen X, Wang Y, Jiang Y, Wang Q, Zhang B, Qian D, Wang J, Zhou D, Ren X, Yu Z, Zhao L, Yuan Z, Wang P and Pang Q. Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist 2021; 26: e1110-e1124.","DOI":"10.1002\/onco.13797"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/OTT.S382967","article-title":"The predictive value of systemic inflammatory factors in advanced, metastatic esophageal squamous cell carcinoma patients treated with camrelizumab","volume":"15","author":"Liu","year":"2022","unstructured":"Liu J, Gao D, Li J, Hu G, Liu J and Liu D. The predictive value of systemic inflammatory factors in advanced, metastatic esophageal squamous cell carcinoma patients treated with camrelizumab. Onco Targets Ther 2022; 15: 1161-1170.","journal-title":"Onco Targets Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"7875627","DOI":"10.1155\/2022\/7875627","article-title":"Synergistic effect of stereotactic radiotherapy combined with karelizumab on patients with advanced NSCLC","volume":"2022","author":"Guo","year":"2022","unstructured":"Guo J, Guo J, Cheng B, Sun X, Zhang H and Ma J. Synergistic effect of stereotactic radiotherapy combined with karelizumab on patients with advanced NSCLC. J Healthc Eng 2022; 2022: 7875627.","journal-title":"J Healthc Eng"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2240689","DOI":"10.1080\/21645515.2023.2240689","article-title":"Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: a case report","volume":"19","author":"Xie","year":"2023","unstructured":"Xie XH, Shen PX, Wu JH, Qiu GH, Lin XQ, Xie ZH, Qin YY, Zheng B, Liu M and Zhou CZ. Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: a case report. Hum Vaccin Immunother 2023; 19: 2240689.","journal-title":"Hum Vaccin Immunother"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"106369","DOI":"10.1016\/j.oraloncology.2023.106369","article-title":"An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: a case report","volume":"140","author":"Hua","year":"2023","unstructured":"Hua Y, Huang X, Li C and Gao N. An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: a case report. Oral Oncol 2023; 140: 106369.","journal-title":"Oral Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41598-023-33038-w","article-title":"Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer","volume":"13","author":"Ma","year":"2023","unstructured":"Ma R, Yuan D, Mo C, Zhu K, Dang C, Zhang Y, Yin J and Li K. Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer. Sci Rep 2023; 13: 6080.","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1117523","DOI":"10.3389\/fimmu.2023.1117523","article-title":"Biomarkers for immunotherapy in esophageal cancer","volume":"14","author":"Wang","year":"2023","unstructured":"Wang X, Wang P, Huang X, Han Y and Zhang P. Biomarkers for immunotherapy in esophageal cancer. Front Immunol 2023; 14: 1117523.","journal-title":"Front Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s12916-023-03132-x","article-title":"A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas","volume":"21","author":"Zhou","year":"2023","unstructured":"Zhou Y, Li M, Zhang B, Yang C, Wang Y, Zheng S, Tang L, Zhou C, Qian G, Huang Y, Yu W, Li H, Wang Y, He A, Shen Z, Zhang J, Li X, Yang Q, Hu H and Yao Y. A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas. BMC Med 2023; 21: 470.","journal-title":"BMC Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/kjm2.12793","article-title":"Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: results from a retrospective study","volume":"40","author":"Kang","year":"2024","unstructured":"Kang NN, Zheng H, Hu JX, Cui K, Si PP and Ge W. Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: results from a retrospective study. Kaohsiung J Med Sci 2024; 40: 291-295.","journal-title":"Kaohsiung J Med Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial","volume":"7","author":"Meng","year":"2022","unstructured":"Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S, Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J and Wang F. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022; 7: 245-253.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/10\/ajtr0158444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:59:59Z","timestamp":1766023199000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/10\/ajtr0158444.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/kmcl5401","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2024]]}}}